Opendata, web and dolomites


Industrial Production of Stable Fibroblast Growth Factors for Regenerative Medicine and Related Research Areas

Total Cost €


EC-Contrib. €






 FGFSTAB project word cloud

Explore the words cloud of the FGFSTAB project. It provides you a very rough idea of what is the project "FGFSTAB" about.

close    thermal    commercial    ulcers    wound    administrations    financial    platform    slow    trauma    gap    trials    fact    surgical    fgfstab    investing    angiogenesis    course    healing    population    additional    see    industrial    lower    biotechnological    fgfs    proteins    cleared    companies    organisms    obesity    demanding    stable    stability    diabetes    authorization    started    hours    frequent    optimization    medicine    technological    despite    engineering    instrument    homeostasis    safe    chronic    tissue    enantis    half    play    care    marketing    limited    stress    body    embryonic    world    incidences    circulation    regenerative    practise    innovative    fibroblast    natural    aging    treatment    heavily    expertise    skin    rising    fgf    necessitating    life    poor    ageing    minutes    dressings    clinical    sme    manufacturing    fireprot    market    primarily    global    closes    greatest    proprietary    effectiveness    therapy    good    goes    protein    risk    adverse   

Project "FGFSTAB" data sheet

The following table provides information about the project.


Organization address
address: KAMENICE 771/34
city: BRNO
postcode: 625 00
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Czech Republic [CZ]
 Project website
 Total cost 1˙030˙000 €
 EC max contribution 1˙030˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2019-02-28


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENANTIS SRO CZ (BRNO) coordinator 1˙030˙000.00


 Project objective

The FGFSTAB project closes the gap between Enantis knowledge and expertise on protein engineering and the commercial applications of stable fibroblast growth factors (FGFs). FGFs are essential to the embryonic development, maintain tissue homeostasis, may slow down ageing of the organisms, and primarily promote angiogenesis and wound healing. FGFs see the greatest application in the care and treatment of chronic skin ulcers, but find use also in surgical and trauma wound healing. The global wound care market is rapidly growing due to the rising aging population and growing incidences of obesity and diabetes. Advanced wound dressings, such as those involving growth factors, play an important role in current regenerative medicine and companies around the world have started investing heavily in research and development of growth factor-based products. However, despite clinical value, applications of FGFs are limited by the fact that natural proteins have poor thermal stability and a short half-life in the circulation; they are often cleared from the body within hours, if not minutes, thus necessitating frequent administrations during the course of treatment, which goes hand in hand with a higher risk of adverse effects and lower cost-effectiveness of the protein therapy. The key objective of the FGFSTAB project is to use an innovative technological platform, based on the application of Enantis proprietary protein optimization concept FireProt, to increase FGF stability under various stress conditions. Additional challenges including high cost of production, current Good Manufacturing Practise, development of delivery systems for safe and effective wound healing, and pre-clinical testing to support future clinical trials and marketing authorization, will be targeted as well. Financial support provided within SME Instrument phase 2 will help us to close the gap from demanding biotechnological development to the target industrial application in regenerative medicine.


List of deliverables.
FGFSTAB web presentation Websites, patent fillings, videos etc. 2019-09-09 15:23:38

Take a look to the deliverables list in detail:  detailed list of FGFSTAB deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FGFSTAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FGFSTAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More